UPDATE ON
Adult Immunization Strategies
Understanding the Current Recommendations

Jointly provided by Center for Independent Healthcare Education and Vemco MedEd

Supported by an educational grant from Merck & Co.
Target Audience
This activity is designed as a comprehensive approach to address the practice needs of primary care providers, including primary care physicians, doctors of osteopathy, physician assistants, nurse practitioners, and allied healthcare professionals, who are at the forefront of caring for adult patients eligible for immunizations and/or at risk for vaccine-preventable diseases.

Learning Objectives
At the conclusion of the educational activity, the learner should be able to:

- Discuss the burden of pneumococcal disease and herpes zoster and identify the various patient types who are particularly vulnerable to infection
- Describe the latest guideline recommendations for adult immunization for prevention of pneumococcal disease and herpes zoster infection
- Evaluate strategies to improve adult immunization by incorporating systems in clinical practice to proactively screen patients and administer vaccines according to guideline recommendations
Faculty and Disclosure

Michael D. Hogue, PharmD, FAPhA, FNAP
Associate Dean, Center for Faith and Health
Professor of Pharmacy
College of Health Sciences
Samford University
McWhorter School of Pharmacy
Birmingham, AL

Michael D. Hogue, PharmD has relevant financial relationships with the following commercial interests:

- Research Support: Merck & Co., Inc.
- Speakers Bureau: Pfizer, Inc.

Dr. Hogue does not intend to discuss the off-label use of any products.

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias.Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Call-to-Action: Recognizing the Burden of Vaccine-Preventable Diseases
Burden of Vaccine-Preventable Diseases

Each Year

- 200,000 hospitalizations due to influenza
  - As many as 36,000 deaths
- 29,100 cases of invasive pneumococcal disease
  - Approximately 3,300 deaths
- 1.25 million people suffer from chronic HBV infection
- Over 1 million people develop shingles
- 17,000 cancers in women and 9,000 cancers in men are caused by HPV.
  - >4,000 cervical cancer deaths

Adult Immunization Coverage, US

- **Pneumococcal**
  - 19-64
  - >65

- **Tdap > 19**

- **Zoster > 60**

- **Influenza > 18**


**MMWR. Feb 5, 2016.** [http://www.cdc.gov/mmwr/volumes/65/ss/ss6501a1.htm](http://www.cdc.gov/mmwr/volumes/65/ss/ss6501a1.htm)
“Prevent all the disease you can, and then treat the rest.”

Michael Hogue
Registries: Not Just for Kids!

Available at: www.cdc.gov/vaccines/programs/iis/about.html
Pneumococcal Disease
Patient Case: Jane Williams

64-year-old patient with a history of renal transplant 5 years ago, taking anti-rejection therapy. History of diabetes and hypertension, both now controlled on medication therapy. Jane is enrolled in a pharmacist-run medication management program in your large group practice. Her immunization history shows influenza vaccine last December at your clinic, and Tdap vaccine in 2013. There is no documentation or recollection of pneumococcal vaccine of any kind. Which pneumococcal vaccine, if any, should she receive today?

1. None.
2. Pneumococcal Polysaccharide Vaccine-23 (PPSV-23)
3. Pneumococcal Conjugate Vaccine-13 (PCV-13)
4. Both PPSV-23 and PCV-13 today
You are seeing Jane today in your family medicine clinic for a routine check up. Given the previous case, which professionals COULD have immunized her already – but apparently did not?

1. Transplant Clinic Nurse/NP/PharmD/MD
2. Pharmacist in Med Management Clinic
3. Pharmacist who provides her Rxs
4. Nurse in your clinic when she received the flu shot
5. All of the above
Making Prevention a Priority

- Family Practice
- Patient
- Specialist
- Home Health
- Pharmacy
- School or Occupational Health
Patient Case: Jon Williams

Jon, Jane’s husband, is 63 years old with a history of diabetes mellitus which is recent onset and well controlled with metformin + lifestyle modification. He is in your family medicine practice today for an annual physical exam. There is no record of Jon having received any immunizations since he last received a Td vaccine 15 years ago following an injury. What pneumococcal vaccine, if any, should Jon receive today?

1. NO pneumococcal immunization
2. PCV13
3. PPSV23
4. PPSV23 today and PCV13 in 1 year
5. PCV13 today and PPSV23 in 1 year
Patient Case: David Summers

David, Jane’s father, is 86 years old and in perfect health. Other than osteoarthritis, he has no chronic conditions. He gets his flu shot every year. No one has ever asked him about a “pneumonia shot”. Which of the following is an accurate pneumococcal vaccine schedule for David?

1. PCV13 now, and done.
2. PPSV23 now, and done.
3. PCV13 now, and PPSV23 in one year
4. PPSV23 now, and PCV 13 in one year
5. PCV 13 now, PPSV 23 in one year, and repeat PPSV23 in 5 years
Pneumococcal Disease Pathogenesis and Burden in Adults Aged ≥50 Years

Streptococcus pneumoniae

Nasopharyngeal colonization

Asymptomatic colonization

Autoinoculation

Pneumonia
302,000 cases (inpatient)
140,000 cases (outpatient)

Bacteremia
7,000 cases

Meningitis
1,700 cases

Pneumococcal Disease

PNEUMOCOCCAL DISEASE:

- Sinusitis
- Otitis media
- Pneumonia

USA

- 4,000,000 cases/year
- 445,000 hosp. admits/year
- 22,000 deaths/year

INVASIVE PNEUMOCOCCAL DISEASE (IPD):

- Bacteremia
- Meningitis
- Sepsis

USA:

- 29,100 cases (9.1/100,000)
- 3250 deaths
- <5 yr: 8.7/100,000
- ≥65: 24.8/100,000


The Incidence of Pneumococcal Disease Increases With Age and Certain Chronic Conditions

IPD, invasive pneumococcal disease.
Many Adults With Pneumococcal Disease Have Underlying Medical Conditions

Frequency of Certain Chronic Conditions Among Adults With IPD — United States

<table>
<thead>
<tr>
<th>Age group</th>
<th>Diabetes mellitus</th>
<th>Chronic heart disease</th>
<th>Chronic lung disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>18–49 years</td>
<td>10%</td>
<td>4%</td>
<td>4%</td>
</tr>
<tr>
<td>(n=1,037)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50–64 years</td>
<td>22%</td>
<td>12%</td>
<td>21%</td>
</tr>
<tr>
<td>(n=1,123)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥65 years</td>
<td>25%</td>
<td>37%</td>
<td>31%</td>
</tr>
<tr>
<td>(n=1,178)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IPD, invasive pneumococcal disease.

Pneumococcal Vaccination

Key Principles

1. Never give PCV-13 and PPSV-23 together at the same visit.

2. Whenever both are indicated, it is best to give PCV-13 first, and follow with PPSV-23 at the appropriate interval.

3. If either vaccine is inadvertently given earlier than the recommended interval, do NOT repeat the dose.

Pneumococcal Vaccines

• **PPSV23**
  - Purified capsular polysaccharide → ‘traditional’ PNC vaccine
  - Contains 23 types—cause ~88% bacteremic pneumococcal disease
  - 60%–70% effectiveness vs. invasive disease
    - Challenge to assess prevention of PNC pneumonia.
  - Immunity lasts at least 5 years following 1 dose
  - FDA-approved for all persons ≥2 years at increased risk for pneumococcal disease
  - Local reactions – only common adverse event

• **PCV13**
  - Conjugate vaccine – results in higher antibody titers
  - Replaced PCV7 for childhood immunization [6 wk–6 yr] in 2010
  - 2011 FDA-approved for adults >50 years: prevent pneumonia, IPD
    - Based on immunogenicity and safety studies
  - 2012 ACIP recommends PCV: IPD prevention, highest-risk adults
    - Highest risk based on anatomic and immunocompromised
    - Best practice: give BEFORE PPSV23
  - 2014 ACIP recommends PCV/PPS combination strategy in aged 65+
  - Local reactions – only common adverse event

In 2013, 38% of IPD among adults aged ≥65 years was caused by serotypes unique to PPSV23

PPSV23 Vaccine Effectiveness

- What is the evidence in preventing IPD and pneumonia?
  - Meta-analysis including 18 RCTs (64,852 participants)

<table>
<thead>
<tr>
<th>Event</th>
<th>No. of RCTs</th>
<th>Event with Vaccine (n/N)</th>
<th>Event with Control (n/N)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPD</td>
<td>11</td>
<td>15/18634</td>
<td>63/17855</td>
<td>0.26 (0.14 to 0.45)</td>
</tr>
<tr>
<td>IPD (vaccine types only)</td>
<td>5</td>
<td>14/13889</td>
<td>140/17334</td>
<td>0.18 (0.10 to 0.31)</td>
</tr>
<tr>
<td>Pneumonia (all causes)</td>
<td>16</td>
<td>978/22643</td>
<td>1547/25091</td>
<td>0.72 (0.56 to 0.93)</td>
</tr>
<tr>
<td>Definitive pneumococcal pneumonia</td>
<td>10</td>
<td>15/18132</td>
<td>60/17351</td>
<td>0.26 (0.15 to 0.46)</td>
</tr>
<tr>
<td>Definitive pneumococcal pneumonia (vaccine types only)</td>
<td>4</td>
<td>3/15583</td>
<td>30/14978</td>
<td>0.13 (0.05 to 0.38)</td>
</tr>
</tbody>
</table>

Protective vaccine efficacy for definitive pneumococcal pneumonia: 74% (95% CI, 54%–85%)

PCV13 Adult Vaccine Effectiveness

CAPiTA

– Placebo-controlled RCT PCV13 unimmunized adults 65+ years
  ▪ Netherlands
    – No routine pneumococcal vaccine in adults
    – PCV7 in Dutch infants since 6/2006 -> PCV10 in March 2011
  – 84,000+ participants PCV13 vs. Placebo
  – Outcomes:
    ▪ **Primary:** Reduced 1st bacteremic CAP with vaccine-type PNC (42%)
    ▪ **Secondary:** Reduced 1st nonbacteremic CAP (41%)
    ▪ **Secondary:** Reduced Invasive PNC over 70%

  – Serologic and urinary Ag used to identify PNC infection
  – DID NOT address sequential PCV13/PPSV23 immunization

Strategies for Sequential Use of Conjugate and Polysaccharide Vaccine Use in Adults

- Conjugate vaccine: more immunogenicity (higher antibody levels) and can have booster effect
  - 13 serogroups (accounts for approximately 50% of invasive cases of pneumococcal disease)

- Polysaccharide vaccine: less immunogenicity and NO booster effect
  - But has 23 serogroups (accounts for approximately 89% of invasive cases)

- Give conjugate first, followed by polysaccharide for potentially optimal effect

- If polysaccharide given initially, wait one year to administer the conjugate vaccine
# Pneumococcal Immunization I

<table>
<thead>
<tr>
<th>PPSV23 ALONE for <strong>INCREASED RISK</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All cigarette smokers ≥19 years to 64 years</strong></td>
</tr>
<tr>
<td><strong>Chronic conditions ≥19 years to 64 years:</strong></td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Lung disease: asthma, COPD</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
</tr>
<tr>
<td>Liver disease, alcoholism</td>
</tr>
<tr>
<td>Kidney disease</td>
</tr>
<tr>
<td>(except ESRD, nephrotic syndrome – HIGHEST risk)</td>
</tr>
</tbody>
</table>

- **REVACCINATION ONCE** after age 65 [PLUS 5 years after initial dose] for those vaccinated prior to age 65
- **Adults 65 years and older:** now in highest risk group. Follow different recommendations.

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm)
[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm)
# Pneumococcal Immunization IIa

## SEQUENTIAL PCV13 + PPSV23: HIGHEST RISK

### Immunocompromised (≥19 YEARS OF AGE):

1. **Disease:**
   - Cancer: solid tumors, hematologic malignancies, myeloma, etc.
   - HIV
   - INHERITED and OTHER immune deficiency (CVID, etc.)
   - End-stage kidney disease (ESRD), nephrotic syndrome

2. **Iatrogenic:**
   - MEDS: Steroids (20+ mg/d), biologic immunomodulators, others
   - TRANSPLANTS: solid organ, bone marrow, stem cell

3. **Asplenia:**
   - ANATOMIC: splenectomy (best if immunized prior to)
   - FUNCTIONAL: hemoglobinopathy, sickle cell, other

### Anatomic (≥19 YEARS OF AGE):

- CSF leak, cochlear implant, splenectomy

**Sequence:** PCV13, then ≥ 8 weeks PPSV23, then 5 years later PPSV23

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a4.htm
## SEQUENTIAL PCV13 + PPSV23: HIGHEST RISK

<table>
<thead>
<tr>
<th>Age: ≥65 years of age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sequence: PCV13 then 1 year later PPSV23 (CDC Preferred Sequencing)</td>
</tr>
</tbody>
</table>

**Caveat:** IF patient has already received PPSV23 on or after age 65, then:
- Single dose of PCV13 at least 1 year after the PPSV23 dose

**Additional Information:**
- Patients over age 65 who received one or more doses of PPSV23 PRIOR to age 65 should still receive one dose each of PCV13 and PPSV23 AFTER age 65.
  - Post-65 dose of PCV13 must be 1 year after pre-65 dose of PPSV23
  - Post-65 dose of PPSV23 must be 1 year after post-65 dose of PCV13 AND must be 5 years after pre-65 dose of PPSV23.

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a4.htm
Millions of Adults at Increased Risk Remain Unvaccinated\textsuperscript{1–4}

What percentage of the \textit{\sim 73 million unvaccinated US adults}\textsuperscript{1} fall into these risk categories?

- All adults aged ≥65 years
- Adults aged ≥19 years who are immunocompetent with certain chronic conditions such as:
  - Diabetes mellitus
  - Chronic heart disease
  - Chronic liver disease
  - Chronic lung disease (COPD)
- Adults aged ≥19 years with immunocompromising conditions or certain other conditions:
  - Immunocompromising conditions including:
    - HIV infection
    - Solid/hematologic cancers
    - Organ transplant
    - Chronic renal failure
    - Nephrotic syndrome
    - Receiving immunosuppressive therapy
  - Functional or anatomic asplenia
  - Cerebrospinal fluid leaks
  - Cochlear implants

\textbf{~39\%} \hspace{3cm} \textbf{~67\%} \hspace{3cm} \textbf{~14\%}

CDC Says Adult Vaccination Rates Are “Unacceptably Low”¹


Vaccination Rate (%)

<table>
<thead>
<tr>
<th>Year</th>
<th>Adults aged ≥65 years</th>
<th>High-risk adults aged &lt;65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>59.7%</td>
<td>18.3%</td>
</tr>
<tr>
<td>2011</td>
<td>62.3%</td>
<td>20.1%</td>
</tr>
<tr>
<td>2012</td>
<td>59.9%</td>
<td>20.0%</td>
</tr>
<tr>
<td>2013</td>
<td>59.7%</td>
<td>21.2%</td>
</tr>
<tr>
<td>2014</td>
<td>61.3%</td>
<td>20.3%</td>
</tr>
</tbody>
</table>

¹Adults with certain underlying medical conditions defined as high risk per the CDC’s Advisory Committee on Immunization Practices.

Call to Action:

Preventing Pneumococcal Disease in US Adults with Chronic Conditions

This initiative is supported by unrestricted educational grants from Merck and Co., Inc. and Pfizer Inc. NPID policies restrict funders from controlling program content.

January 2015
<table>
<thead>
<tr>
<th>Risk Group</th>
<th>Underlying Medical Condition</th>
<th>PCV13</th>
<th>PPSV23</th>
<th>Revaccination 5 years After First Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunocompetent persons</td>
<td>Chronic heart disease†</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic lung disease§</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetes mellitus</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cerebrospinal fluid leak</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cochlear implant</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alcoholism</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic liver disease, cirrhosis</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cigarette smoking</td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Persons with functional or anatomic asplenia</td>
<td>Sickle cell disease/other hemoglobinopathy</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Congenital or acquired asplenia</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Immunocompromised persons</td>
<td>Congenital or acquired immunodeficiency†</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Human immunodeficiency virus infection</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Chronic renal failure</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Nephrotic syndrome</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Leukemia</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Lymphoma</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Hodgkin disease</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Generalized malignancy</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Iatrogenic immunosuppression**</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Solid organ transplant</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Multiple myeloma</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
</tbody>
</table>

*All adults age 65 years and older should receive a dose of PPSV23, regardless of previous pneumococcal vaccination history.
† Including congestive heart failure and cardiomyopathies, excluding hypertension.
§ Including chronic obstructive pulmonary disease, emphysema, and asthma.
¶ Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).
** Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.
Herpes Zoster (Shingles)
Healthy 67-year-old man who returns for wellness visit. He smokes 3 cigars a week and had an episode of shingles 5 months ago. He received high-dose influenza vaccine from his local pharmacy in September and pneumococcal vaccine 1 year ago. Which of the following is the most correct regarding zoster immunization for Don?

1. No Zoster vaccination; he had previous shingles
2. No Zoster vaccination today; can’t be administered with PPSV23
3. Zoster vaccine today
4. Zoster vaccine today and booster vaccination in 5–10 years
Zoster

- Most who have varicella have Ab for life
  - Zoster occurs when cell-mediated immunity (CMI) surveillance declines
  - Reactivation or varicella exposure re-stimulates CMI
  - Cycle can repeat multiple times
- Lifetime risk of Zoster ~33%
  - By age 85: risk ~50%
  - PHN= most common AE
    - Up to 1/3 patients with Zoster
    - More common
      - >70 years with Zoster
      - Immunocompromised
- Vaccination stimulates CMI

PHN, postherpetic neuralgia.
Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm
Zoster Pathophysiology

- Reactivation of a latent Varicella zoster virus
  - Promptly or decades after chickenpox
- Trigger factors
  - Reduced immunocompetence
  - Trauma
  - Normal aging
- Estimated 1 million cases annually in the US
- Adults at greatest risk:
  - Immunocompromised conditions (e.g., malignancy, HIV)
  - Taking immunosuppressive medications (e.g., steroids, rheumatoid arthritis meds)

Center for Disease Control and Prevention. Shingles (Herpes Zoster). Available at: www.cdc.gov/shingles/about/overview.html
Complications of Zoster

- Scarring and keloid formation; secondary skin infection of skin lesions
- Visceral zoster and encephalitis
- Corneal damage and blindness
- Pneumonia (viral or bacterial)
- Postherpetic neuralgia (PHN)
  - Pain in the dermatome of rash after rash heals
  - Criteria: 90 (or 120) days after rash onset
  - Pain can last months to years
  - As people get older, more likely to develop PHN and the pain is more likely to be severe

Centers for Disease Control and Prevention. Shingles (Herpes Zoster). Available at: www.cdc.gov/shingles/about/overview.html
Duration of Pain after Rash Heals Increases With Age

de Moragas JM, Kierland RR. *AMA Arch Derm.* 1957;75:193-196.
Vaccine Efficacy Trial:

- 38,546 Veterans  Median age: 69 years
  - 60–69 years: 20,747  [Efficacy greatest in this group]
  - ≥70 years: 17,799 (46%)
  - ≥80 years: ~2,500 (6.5%)
  - Excluded: Immunocompromised, prior zoster, <60 yrs.

- Vaccine group had [vs. placebo]:
  - 51% fewer episodes of zoster
  - Less severe disease
  - 66% less postherpetic neuralgia

- No significant safety issues were identified

Zoster

- Vaccinate HEALTHY adults 60+ years old
- ACIP: NOT IMMUNOCOMPROMISED
  - FDA-approved from age 50 differs from ACIP recommendation
  - Regardless of prior Zoster [arbitrary CDC opinion: wait 1 year]
  - No need to test/vaccinate vs. varicella first
- Contraindications
  - Pregnancy
  - Anaphylactic hypersensitivity to neomycin, gelatin
  - No need to defer for ‘at-risk contacts’– transmission risk low
  - No need to defer if recent transfusion, Ab-containing products
- Adverse events
  - Occasional mild varicella-like rash at vaccine site
- Frozen vaccine: Give w/in 60 minutes, 0.65 mL SQ deltoid
- Duration of protection: At least 4 years. No booster.

Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm
Zoster: Special Populations

- Prior to Immune Suppression
  - American College of Rheumatology recommends Zoster vaccine [2008] in age 50+ years
  - Recommend off IS × 4 weeks after vaccine
  - Poster ACR 2014:
    - Zoster vaccine in 57 patients on biologics SQ, IV
    - NO disseminated Zoster
    - Study ongoing…

- HIV
  - No recommendation for vaccination
  - Studies of vaccination in immune-reconstituted HIV patients are underway

- No Publication Data
  - Revaccination, vaccination before age 50 years

Zoster: Special Consideration

- Simultaneous administration of pneumococcal vaccine
  - One study showed the average titer against varicella zoster virus (VZV) was lower in persons who received zoster and PPSV23 at the same visit compared to persons who received these vaccines 4 weeks apart.
  
  - However, a large study was subsequently conducted that showed that zoster vaccine was equally effective at preventing herpes zoster whether it was administered simultaneously with PPSV23 or 4 weeks earlier.

  - CDC continues to recommend that HZV and PPSV23 be administered at the same visit if the person is eligible for both vaccines.
General Practice Recommendations
NVAC Goals

The goals are as follows:

Goal 1: Strengthen the adult immunization infrastructure.
Goal 2: Improve access to adult vaccines.
Goal 3: Increase community demand for adult immunizations.
Goal 4: Foster innovation in adult vaccine development and vaccination-related technologies.

Vaccine Storage and Handling

Key Messages:

⊙ The vaccine cold chain is a temperature-controlled environment used to maintain and distribute vaccines in optimal condition.

⊙ Monitor the temperature of your storage unit(s) regularly to assure that appropriate conditions are maintained.

⊙ Take immediate corrective action when a storage unit temperature is outside the recommended range (Troubleshooting).

⊙ Call the vaccine manufacturer for guidance.

⊙ If you are a VFC provider or have other vaccines purchased with public funds, contact your immunization program 🔄.

⊙ Vaccine appearance is NOT a reliable indicator that vaccines have been stored under appropriate conditions.

⊙ Vaccine exposed to inappropriate temperatures that is inadvertently administered generally should be repeated. Contact your immunization program 🔄, vaccine manufacturer(s), or both for guidance.

Available at: http://www.cdc.gov/vaccines/recs/storage/toolkit/storage-handling-toolkit.pdf
Immunosuppression and Vaccines

- **Live vaccines** should be administered ≥4 weeks prior to planned immunosuppression.
- **Inactivated vaccines** should be administered ≥2 weeks prior to planned immunosuppression.
- Specialists and primary care providers share responsibility for immunizing immunosuppressed patients and their family members.

Take Home Points

Per CDC:

- **ASSESS** vaccination status of all patients in every clinical encounter

- **Strongly RECOMMEND** vaccines that patients need

- **ADMINISTER** needed vaccines or **REFER** to a provider who can vaccinate

- **DOCUMENT** vaccines received by your patients

Learning by Sharing: Q and A
UPDATE ON

Adult Immunization Strategies

Understanding the Current Recommendations

Jointly provided by Center for Independent Healthcare Education and Vemco MedEd

Supported by an educational grant from Merck & Co.